Oncology

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

With its new Series A, Aton Health isn't just growing; it's validating a model where research is seamlessly integrated into routine patient care.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

As youth nicotine pouch use soars, Imperial Tobacco Canada calls for a crackdown on illicit sales. But is this a genuine public health plea or a masterful play to secure its market?

Leveraged finance titans turned a personal fight into a philanthropic powerhouse, raising a record $4.3M to fund the science that’s turning the tide on melanoma.

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

A novel case study reveals how targeted chemotherapy delivery is outsmarting stubborn tumors, highlighting a metabolic victory even when size remains unchanged.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.